A CME review on keratinocyte carcinoma says noninvasive diagnostic tools — including dermoscopy, reflectance confocal microscopy, optical coherence tomography, electrical impedance spectroscopy, tape stripping, and artificial intelligence — can help identify basal cell and squamous cell carcinoma while reducing unnecessary skin biopsies. The review highlights especially strong value in older adults, immunocompromised patients, cosmetically sensitive areas, and people with biopsy fatigue, fear, or contraindications to biopsy.

Why It Matters To Your Practice

• You’re often the first clinician to spot a suspicious lesion, so better bedside tools can sharpen your diagnostic confidence without waiting for a procedure slot.

• Keratinocyte carcinoma is the most common cancer in the U.S., and incidence is rising, especially in patients older than 65 and those who are immunocompromised.

• For NPs and PAs managing high-volume skin complaints, noninvasive options can support smarter triage: reassure, monitor, biopsy, or refer.

Clinical Benefits

• Dermoscopy can improve visual assessment of lesions beyond the naked-eye exam.

• Reflectance confocal microscopy and optical coherence tomography may offer added structural detail when the diagnosis is uncertain.

• Electrical impedance spectroscopy, tape stripping for genetic material or proteins, and AI-based tools represent emerging ways to assess lesions with less disruption to patients.

• These approaches may be especially useful in cosmetically sensitive sites or when patients are poor candidates for biopsy.

Managing Risks

• These tools are adjuncts, not replacements for clinical judgment, biopsy, or specialist referral when malignant neoplasm is strongly suspected.

• Access, training, device availability, and reimbursement may limit real-world use in some practices.

• Be cautious about overrelying on newer technologies that may vary in validation, workflow fit, and operator experience.

• Patients with changing, bleeding, painful, or high-risk lesions still need timely escalation even if a noninvasive test is reassuring.

The Bottom Line

• Noninvasive diagnostics are expanding your frontline toolkit for keratinocyte carcinoma.

• For NPs and PAs, that means more than convenience: it reinforces your central role in early detection, risk stratification, and patient-centered skin cancer care.

• Used well, these tools can help reduce unnecessary biopsies while identifying which lesions truly need tissue diagnosis.